For Publishers
DiscoveryMetadataPeer reviewHostingPublishing
For Researchers
JoinPublishReviewCollect
Register
Blog
About
Search
Advanced search
My ScienceOpen
Search
For Publishers
For Researchers
Blog
About
53
views
131
references
 Top references
cited by
330
    
0 reviews
 Review
0
comments
 Comment
0
recommends
+1 Recommend
1 collections
    0
    shares
      410
      similar
       All similar
      • Record: found
      • Abstract: found
      • Article: found

      Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update.

      Read this article at

      ScienceOpenPublisherPubMed
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          To provide updated recommendations about prophylaxis and treatment of venous thromboembolism (VTE) in patients with cancer.

          Related collections

          Most cited references131

          • Record: found
          • Abstract: not found
          • Article: not found

          Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update

          Betty Ferrell, Jennifer Temel, Sarah Temin … (2017)
          Article 0 comments Cited 325 times – based on 0 reviews     Review now
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Epidemiology of venous thromboembolism.

            John Heit (2015)
            Thrombosis can affect any venous circulation. Venous thromboembolism (VTE) includes deep-vein thrombosis of the leg or pelvis, and its complication, pulmonary embolism. VTE is a fairly common disease, particularly in older age, and is associated with reduced survival, substantial health-care costs, and a high rate of recurrence. VTE is a complex (multifactorial) disease, involving interactions between acquired or inherited predispositions to thrombosis and various risk factors. Major risk factors for incident VTE include hospitalization for surgery or acute illness, active cancer, neurological disease with leg paresis, nursing-home confinement, trauma or fracture, superficial vein thrombosis, and-in women-pregnancy and puerperium, oral contraception, and hormone therapy. Although independent risk factors for incident VTE and predictors of VTE recurrence have been identified, and effective primary and secondary prophylaxis is available, the occurrence of VTE seems to be fairly constant, or even increasing.
            Article 0 comments Cited 289 times – based on 0 reviews     Review now
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Development and validation of a predictive model for chemotherapy-associated thrombosis.

              Alok A. Khorana, Nicole M Kuderer, Eva Culakova … (2008)
              Risk of venous thromboembolism (VTE) is elevated in cancer, but individual risk factors cannot identify a sufficiently high-risk group of outpatients for thromboprophylaxis. We developed a simple model for predicting chemotherapy-associated VTE using baseline clinical and laboratory variables. The association of VTE with multiple variables was characterized in a derivation cohort of 2701 cancer outpatients from a prospective observational study. A risk model was derived and validated in an independent cohort of 1365 patients from the same study. Five predictive variables were identified in a multivariate model: site of cancer (2 points for very high-risk site, 1 point for high-risk site), platelet count of 350 x 10(9)/L or more, hemoglobin less than 100 g/L (10 g/dL) and/or use of erythropoiesis-stimulating agents, leukocyte count more than 11 x 10(9)/L, and body mass index of 35 kg/m(2) or more (1 point each). Rates of VTE in the derivation and validation cohorts, respectively, were 0.8% and 0.3% in low-risk (score = 0), 1.8% and 2% in intermediate-risk (score = 1-2), and 7.1% and 6.7% in high-risk (score >/= 3) category over a median of 2.5 months (C-statistic = 0.7 for both cohorts). This model can identify patients with a nearly 7% short-term risk of symptomatic VTE and may be used to select cancer outpatients for studies of thromboprophylaxis.
              Article 0 comments Cited 271 times – based on 0 reviews     Review now
                Bookmark
                All references

                Author and article information

                Journal
                Journal ID (iso-abbrev): J. Clin. Oncol.
                Title: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
                Publisher: American Society of Clinical Oncology (ASCO)
                ISSN (Electronic): 1527-7755
                ISSN (Print): 0732-183X
                Publication date (Electronic): Feb 10 2020
                Volume: 38
                Issue: 5
                Affiliations
                [1 ] University of North Carolina, Chapel Hill, NC.
                [2 ] Cleveland Clinic, Cleveland, OH.
                [3 ] Advanced Cancer Research Group and University of Washington, Seattle, WA.
                [4 ] American Society of Clinical Oncology, Alexandria, VA.
                [5 ] BC Cancer Agency, Vancouver, British Columbia, Canada.
                [6 ] University of Granada, Granada, Spain.
                [7 ] Dartmouth-Hitchcock Medical Center, Lebanon, NH.
                [8 ] Penn State Cancer Institute, Hershey, PA.
                [9 ] Emory University, Atlanta, GA.
                [10 ] James P Wilmot Cancer Center and University of Rochester, Rochester, NY.
                [11 ] Patient Representative, Denver, CO.
                [12 ] Thrombosis Research Institute and University College, London, United Kingdom.
                [13 ] McMaster University, Hamilton, Ontario, Canada.
                [14 ] University of Southern California and Norris Comprehensive Cancer Center, Los Angeles, CA.
                [15 ] University of California, San Francisco, San Francisco, CA.
                [16 ] Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA.
                [17 ] Hospital Papa Giovanni XXIII, Bergamo; and University of Milan Bicocca, Milan, Italy.
                Article
                DOI: 10.1200/JCO.19.01461
                PubMed ID: 31381464
                SO-VID: 2967e449-5d4c-4e10-905b-dce0f4f2e5f4
                History

                Data availability:

                Comments

                Comment on this article

                scite_

                Similar content410

                See all similar

                Cited by361

                See all cited by

                Most referenced authors1,857

                See all reference authors